Literature DB >> 18824744

Skeletal myoblasts preserve remote matrix architecture and global function when implanted early or late after coronary ligation into infarcted or remote myocardium.

Patrick Farahmand1, Teresa Y Y Lai, Richard D Weisel, Shafie Fazel, Terrence Yau, Philippe Menasche, Ren-Ke Li.   

Abstract

BACKGROUND: The inability of skeletal myoblasts to transdifferentiate into cardiomyocytes suggests that their beneficial effects on cardiac function after a myocardial infarction are mediated by paracrine effects. We evaluated the roles of these factors in the preservation of matrix architecture (in the infarct and remote regions) by varying the timing (postmyocardial infarction) and delivery site of the implanted cells. METHODS AND
RESULTS: Skeletal myoblasts (5x10(6)) or control media were injected into the infarct or noninfarcted myocardium at 5 or 30 days after coronary artery ligation in rats. Function was assessed by echocardiography before transplantation and 14 and 30 days thereafter and with a Millar catheter at 30 days after transplantation. Ventricular geometry, remote fibrillar collagen architecture, and changes in the matrix metalloproteinase-TIMP system were evaluated. Myoblast implantation in both sites and at both times preserved matrix architecture (length and width of collagen fibers) in the remote myocardium (in association with some decreases in remote myocardial matrix metalloprotease activity), improved global cardiac function, and attenuated the progressive increase in end diastolic volume (P<0.05 for all measures compared with medium controls). Cells delivered into the infarct region preserved scar thickness; cells delivered into the noninfarcted myocardium preserved wall thickness.
CONCLUSIONS: Regardless of whether the cells were injected into the infarct or the noninfarcted myocardium early after an myocardial infarction or later, skeletal myoblasts improved cardiac function by preventing ventricular dilation and preserving matrix architecture in the remote region, likely mediated by paracrine effects.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18824744     DOI: 10.1161/CIRCULATIONAHA.107.757617

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  20 in total

Review 1.  De novo myocardial regeneration: advances and pitfalls.

Authors:  Khawaja Husnain Haider; Stephanie Buccini; Rafeeq P H Ahmed; Muhammad Ashraf
Journal:  Antioxid Redox Signal       Date:  2010-10-12       Impact factor: 8.401

Review 2.  Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions.

Authors:  Santosh K Sanganalmath; Roberto Bolli
Journal:  Circ Res       Date:  2013-08-30       Impact factor: 17.367

Review 3.  Bioengineered tissue solutions for repair, correction and reconstruction in cardiovascular surgery.

Authors:  Laura Iop; Tiziana Palmosi; Eleonora Dal Sasso; Gino Gerosa
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

4.  Human adipose tissue-derived stem cells exhibit proliferation potential and spontaneous rhythmic contraction after fusion with neonatal rat cardiomyocytes.

Authors:  Roxana Metzele; Christopher Alt; Xiaowen Bai; Yasheng Yan; Zhi Zhang; Zhizhong Pan; Michael Coleman; Jody Vykoukal; Yao-Hua Song; Eckhard Alt
Journal:  FASEB J       Date:  2010-11-08       Impact factor: 5.191

Review 5.  Striated muscle function, regeneration, and repair.

Authors:  I Y Shadrin; A Khodabukus; N Bursac
Journal:  Cell Mol Life Sci       Date:  2016-06-06       Impact factor: 9.261

Review 6.  "Second-generation" stem cells for cardiac repair.

Authors:  Alberto Núñez García; Ricardo Sanz-Ruiz; María Eugenia Fernández Santos; Francisco Fernández-Avilés
Journal:  World J Stem Cells       Date:  2015-03-26       Impact factor: 5.326

Review 7.  Cardiovascular surgery for realization of regenerative medicine.

Authors:  Hidetoshi Masumoto; Ryuzo Sakata
Journal:  Gen Thorac Cardiovasc Surg       Date:  2012-08-30

Review 8.  Stem cell therapy for chronic myocardial infarction.

Authors:  Manuel Mazo; Beatriz Pelacho; Felipe Prósper
Journal:  J Cardiovasc Transl Res       Date:  2010-01-21       Impact factor: 4.132

Review 9.  Preconditioning and stem cell survival.

Authors:  Husnain Kh Haider; Muhammad Ashraf
Journal:  J Cardiovasc Transl Res       Date:  2009-12-22       Impact factor: 4.132

Review 10.  Stem cell therapy for chronic heart failure: an updated appraisal.

Authors:  Simon Maltais; Steven J Joggerst; Antonis Hatzopoulos; Thomas G DiSalvo; David Zhao; Hak-Joon Sung; Xintong Wang; John G Byrne; Allen J Naftilan
Journal:  Expert Opin Biol Ther       Date:  2013-01-06       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.